MA
HZNP

MCF Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

MCF Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,453
Closed -$168K – 1001
2023
Q3 		$168K Sell
1,453
-731
-33% -$78.5K 0.02% 232
2023
Q2 		$225K Buy
2,184
+2,057
+1,620% +$217K 0.02% 202
2023
Q1 		$13.9K Hold
127
– – ﹤0.01% 529
2022
Q4 		$14.5K Hold
127
– – ﹤0.01% 489
2022
Q3 		$8K Hold
127
– – ﹤0.01% 584
2022
Q2 		$10K Hold
127
– – ﹤0.01% 511
2022
Q1 		$13K Hold
127
– – ﹤0.01% 506
2021
Q4 		$14K Hold
127
– – 0.3% 18
2021
Q3 		$14K Buy
+127
New +$13.2K ﹤0.01% 459

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

MCF Advisors's HZNP Position: Q4 2023 in Review

MCF Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 1,453 shares — an estimated $168K sold.

MCF Advisors first reported a position in HZNP in Q3 2021 and held it in 9 quarters. The position peaked at $225K in Q2 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • MCF Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • MCF Advisors sold 1,453 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $168K.
  • MCF Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 9 quarters.
  • MCF Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $225K in Q2 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on MCF Advisors's 13F filing for Q4 2023, filed 1 Feb 2024.